Tool to predict your 2-year risk of late age-related macular degeneration
Official title: A Model for Predicting 2-Year Risk of Incident Late Age-related Macular Degeneration
Funded at Ihealthscreen, INC. · NIH-11146532 · Data updated 2026-11-12
This AI tool predicts whether people with early or intermediate age-related macular degeneration are likely to develop late AMD within two years.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ihealthscreen, INC. NIH-funded |
| Lab location | 1 site (Richmond Hill, UNITED STATES) |
| Project start | May 1, 2021 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $698,032 |
| NIH project number | 5R44EY031202-05 |
| Project ID | NIH-11146532 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with early or intermediate age-related macular degeneration who can attend eye imaging and follow-up visits.
✕Less likely to help
People who already have late (advanced) AMD or vision loss from other eye diseases are unlikely to benefit from this prediction tool.
What this research studies
You would have your eye images and clinical information analyzed by an AI program called iPredict-AMD, and researchers will follow you to see if the tool correctly predicts who develops late AMD over two years. The project includes prospective clinical trials plus human factors and precision studies to validate the software for FDA clearance and commercial use. Participation may involve retinal imaging, regular follow-up visits, and permission to use your data for analysis. The goal is to improve early detection so doctors can tailor monitoring and treatment.
Why it matters
Potential benefit: If successful, this could help people with early AMD learn their short-term risk and get closer monitoring or earlier treatment to help protect vision.
How similar studies have gone: Similar AI models and risk scores have shown promise in retrospective studies, but prospective clinical validation for two-year prediction of late AMD is still limited.
Where this research is happening
-
Ihealthscreen, INC.
Richmond Hill, United States Active
Researchers
- Principal investigator: Bhuiyan, Alauddin — Ihealthscreen, INC.
- Study coordinator: Bhuiyan, Alauddin
Related research
Other NIH-funded projects on the same topics.
-
AI-powered tool to predict 2-year risk of late AMD
A new AI software helps people at risk of age-related macular degeneration understand their 2-year risk and what steps could protect their vision.
-
Active cycling program to support vision and daily living in Veterans with AMD
A 6-month online group spin cycling program is tested to help Veterans with age-related macular degeneration maintain vision and improve daily functioning.
-
Transplanting stem-cell–derived retinal cells to treat dry AMD
A medical team is testing a stem cell therapy to replace damaged retinal cells in adults with dry age-related macular degeneration.
-
RPESC-derived RPE Transplant for Dry AMD in adults
A new cell-based therapy derived from RPESCs is being tested to help adults with dry age-related macular degeneration regain vision.
-
New high-resolution OCT biomarkers to map early AMD changes
A new imaging approach using advanced OCT methods will help doctors see early changes in age-related macular degeneration to guide treatment and improve quality of life for older adults.
-
Targeting inflammation in age-related macular degeneration
Aims to understand how inflammation drives age-related macular degeneration in people and explore new targets to slow or stop vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.